Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

Ophthalmology

Volumn 126, Issue 8, 2019, Pages 1155-1170

  Sahni, Jayashree ^a   Patel, Sunil S ^b   Dugel, Pravin U ^c,d   Khanani, Arshad M ^e,f   Jhaveri, Chirag D ^g,h   Wykoff, Charles C ^i,j   Hershberger, Vrinda S ^k   Pauly Evers, Meike ^a   Sadikhov, Shamil ^a   Szczesny, Piotr ^a   Schwab, Dietmar ^a   Nogoceke, Everson ^a   Osborne, Aaron ^l   Weikert, Robert ^a   Fauser, Sascha ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b West Texas Retina   (United States)

^c RETINAL CONSULTANTS OF ARIZONA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Sierra Eye Associates   (United States)

^f UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^g Retina Consultants of Austin and Retina Research Center   (United States)

^h UNIVERSITY OF TEXAS AT AUSTIN   (United States)

ⁱ RETINA CONSULTANTS OF HOUSTON   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k Florida Eye Associates   (United States)

^l GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; FARICIMAB; HEMOGLOBIN A1C; RANIBIZUMAB; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; ANGPT2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BLURRED VISION; CATARACT; CENTRAL SUBFIELD THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE PAIN; EYELID EDEMA; FEMALE; FOLLOW UP; HUMAN; LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA EXUDATE; RETINA VEIN OCCLUSION; SINGLE DRUG DOSE; SUBCAPSULAR CATARACT; UNITED STATES; VISUAL SYSTEM PARAMETERS; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85064563040     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2019.03.023     Document Type: Article

References (44)

1. Guariguata, L., Whiting, D.R., Hambleton, I., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
2. Ting, D.S., Cheung, G.C., Wong, T.Y., Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 44 (2016), 260–277.
3. Lee, R., Wong, T.Y., Sabanayagam, C., Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond), 2, 2015, 17.
4. Boyer, D.S., Hopkins, J.J., Sorof, J., Ehrlich, J.S., Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 4 (2013), 151–169.
5. Fong, D.S., Aiello, L.P., Ferris, F.L., Klein, R., Diabetic retinopathy. Diabetes Care 27 (2004), 2540–2553.
6. Yau, J.W., Rogers, S.L., Kawasaki, R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35 (2012), 556–564.
7. Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res, 2016, 2016, 2156273.
8. Cheung, N., Mitchell, P., Wong, T.Y., Diabetic retinopathy. Lancet 376 (2010), 124–136.
9. Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119 (2012), 789–801.
10. Brown, D.M., Nguyen, Q.D., Marcus, D.M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120 (2013), 2013–2022.
11. Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121 (2014), 2247–2254.
12. Brown, D.M., Schmidt-Erfurth, U., Do, D.V., et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122 (2015), 2044–2052.
13. Cohen, S.R., Gardner, T.W., Diabetic retinopathy and diabetic macular edema. Dev Ophthalmol 55 (2016), 137–146.
14. Ciulla, T.A., Bracha, P., Pollack, J., Williams, D.F., Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina 2 (2018), 1179–1187.
15. Holekamp, N.M., Campbell, J., Almony, A., et al. Vision outcomes following anti–vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol 191 (2018), 83–91.
16. ® Registry (Intelligent Research in Sight). Invest Ophthalmol Vis Sci, 59, 2018, 2604.
17. Klaassen, I., Van Noorden, C.J., Schlingemann, R.O., Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 34 (2013), 19–48.
18. Scholz, A., Plate, K.H., Reiss, Y., Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci 1347 (2015), 45–51.
19. Rubio, R.G., Adamis, A.P., Ocular angiogenesis: vascular endothelial growth factor and other factors. Dev Ophthalmol 55 (2016), 28–37.
20. Campochiaro, P.A., Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res 49 (2015), 67–81.
21. Saharinen, P., Eklund, L., Alitalo, K., Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov 16 (2017), 635–661.
22. Sato, T.N., Tozawa, Y., Deutsch, U., et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376 (1995), 70–74.
23. Oh, H., Takagi, H., Suzuma, K., et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274 (1999), 15732–15739.
24. Ohashi, H., Takagi, H., Koyama, S., et al. Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis 10 (2004), 608–617.
25. Rangasamy, S., Srinivasan, R., Maestas, J., et al. A potential role for angiopoietin 2 in the regulation of the blood–retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 52 (2011), 3784–3791.
26. Park, S.W., Yun, J.-H., Kim, J.H., et al. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes 63 (2014), 3057–3068.
27. Lee, S.G., Lee, C.G., Yun, I.H., et al. Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clin Exp Ophthalmol 40 (2012), e47–e57.
28. Huang, H., Bhat, A., Woodnutt, G., Lappe, R., Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10 (2010), 575–585.
29. Ferrara, N., Adamis, A.P., Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15 (2016), 385–403.
30. Fuxe, J., Tabruyn, S., Colton, K., et al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol 178 (2011), 2897–2909.
31. Gerald, D., Chintharlapalli, S., Augustin, H.G., Benjamin, L.E., Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73 (2013), 1649–1657.
32. Regula, J.T., Lundh von Leithner, P., Foxton, R., et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8 (2016), 1265–1288.
33. Foxton, R.H., Uhles, S., Gruener, S., et al. Evaluation of the effects of VEGF/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model. Invest Ophthalmol Vis Sci, 59, 2018, 237.
34. Schaefer, W., Regula, J.T., Bähner, M., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Nat Acad Sci U S A 108 (2011), 11187–11192.
35. Chakravarthy, U., Bailey, C., Brown, D.M., et al. Phase I trial of anti–vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina 1 (2017), 474–485.
36. Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118 (2011), 615–625.
37. Dugel, P.U., Hillenkamp, J., Sivaprasad, S., et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol 10 (2016), 1103–1110.
38. Do, D.V., Sepah, Y.J., Boyer, D., et al. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the Macula in Diabetes-Protocol 3 with high dose). Eye (Lond) 29 (2015), 1538–1544.
39. Massin, P., Bandello, F., Garweg, J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33 (2010), 2399–2405.
40. Boyer, D.S., Intravitreal nesvacumab+aflibercept in diabetic macular edema: the phase 2 RUBY trial. Invest Ophthalmol Vis Sci, 59, 2018, 3620.
41. Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123 (2016), 1351–1359.
42. Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372 (2015), 1193–1203.
43. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Faricimab (R06867461) in Participants with Diabetic Macular Edema (YOSEMITE). https://clinicaltrials.gov/ct2/show/NCT03622580 Accessed 25.10.18.
44. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Faricimab (R06867461) in Participants with Diabetic Macular Edema (RHINE). https://clinicaltrials.gov/ct2/show/NCT03622593 Accessed 25.10.18.